Goldman Sachs
RARX

Goldman Sachs’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Goldman Sachs’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,014,822
Closed -$48.7M – 5672
2020
Q1 		$48.7M Buy
1,014,822
+367,716
+57% +$17.1M 0.02% 873
2019
Q4 		$30.4M Buy
647,106
+83,387
+15% +$3.69M 0.01% 1521
2019
Q3 		$13.3M Buy
563,719
+348,385
+162% +$10.3M ﹤0.01% 2128
2019
Q2 		$6.47M Sell
215,334
-6,042
-3% -$138K ﹤0.01% 2658
2019
Q1 		$4.96M Buy
221,376
+21,667
+11% +$466K ﹤0.01% 2978
2018
Q4 		$3.63M Buy
199,709
+107,651
+117% +$1.69M ﹤0.01% 3144
2018
Q3 		$1.67M Sell
92,058
-41,735
-31% -$495K ﹤0.01% 3724
2018
Q2 		$1.33M Buy
133,793
+59,862
+81% +$413K ﹤0.01% 3887
2018
Q1 		$393K Buy
73,931
+44,994
+155% +$322K ﹤0.01% 4631
2017
Q4 		$246K Buy
28,937
+12,516
+76% +$154K ﹤0.01% 5300
2017
Q3 		$240K Sell
16,421
-56,682
-78% -$857K ﹤0.01% 5643
2017
Q2 		$1.37M Buy
73,103
+4,751
+7% +$107K ﹤0.01% 4169
2017
Q1 		$1.46M Buy
+68,352
New +$1.31M ﹤0.01% 4044

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Goldman Sachs's RARX Position: Q2 2020 in Review

Goldman Sachs sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,014,822 shares — an estimated $48.7M sold.

Goldman Sachs first reported a position in RARX in Q1 2017 and held it in 13 quarters. The position peaked at $48.7M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Goldman Sachs reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,014,822 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $48.7M.
  • Goldman Sachs first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 13 quarters.
  • Goldman Sachs's Ra Pharmaceuticals, Inc. Common Stock position peaked at $48.7M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.